TXN and lymphoma: These data nominate the PRPS1 isozyme as a completely new potential therapeutic target in Myc-overexpressing lymphomas, as PRPS1 KO cells are sensitive to oxidative stressors that specifically interfere with the NADPH-dependent reductive activity of the thioredoxin and glutathione pathways.